Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.575 USD | -2.45% | -11.97% | -35.11% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.11% | 194M | |
+5.67% | 217B | |
+9.27% | 190B | |
+19.47% | 141B | |
+29.96% | 110B | |
+1.63% | 64.8B | |
+15.28% | 52.44B | |
+3.01% | 49.94B | |
-4.82% | 42.63B | |
+1.92% | 35.81B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Transcript : NeuroPace, Inc., Q2 2022 Earnings Call, Aug 11, 2022